MT1A, a member of the metallothionein (MT) family, is involved in tumour development, progression, and drug resistance, essential for metal homeostasis and cellular stress protection, with its variable expression across cancer types indicating its potential as a biomarker for cancer diagnosis and prognosis, as well as a target for therapeutic intervention [59]. Here, MT1A is linked to neoplasm.